Becton, Dickinson and Company (NYSE:BDX) EVP Sells $399,269.15 in Stock

Becton, Dickinson and Company (NYSE:BDX) EVP Michael David Garrison sold 1,715 shares of the business’s stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the transaction, the executive vice president now owns 5,381 shares of the company’s stock, valued at approximately $1,252,750.61. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Becton, Dickinson and Company Stock Performance

NYSE BDX opened at $233.81 on Thursday. Becton, Dickinson and Company has a 1 year low of $229.40 and a 1 year high of $287.32. The firm has a market capitalization of $67.55 billion, a P/E ratio of 55.41, a price-to-earnings-growth ratio of 1.93 and a beta of 0.43. The firm’s fifty day moving average price is $238.75 and its two-hundred day moving average price is $240.71. The company has a current ratio of 1.08, a quick ratio of 0.64 and a debt-to-equity ratio of 0.56.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, February 1st. The medical instruments supplier reported $2.68 EPS for the quarter, beating the consensus estimate of $2.39 by $0.29. Becton, Dickinson and Company had a net margin of 6.44% and a return on equity of 13.57%. The firm had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.73 billion. During the same period in the previous year, the company earned $2.98 earnings per share. The company’s quarterly revenue was up 2.6% on a year-over-year basis. As a group, research analysts anticipate that Becton, Dickinson and Company will post 12.94 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Monday, June 10th will be issued a $0.95 dividend. The ex-dividend date of this dividend is Monday, June 10th. This represents a $3.80 annualized dividend and a dividend yield of 1.63%. Becton, Dickinson and Company’s dividend payout ratio is currently 90.05%.

Hedge Funds Weigh In On Becton, Dickinson and Company

Institutional investors and hedge funds have recently modified their holdings of the stock. Jeppson Wealth Management LLC grew its stake in shares of Becton, Dickinson and Company by 4.0% in the third quarter. Jeppson Wealth Management LLC now owns 1,028 shares of the medical instruments supplier’s stock valued at $266,000 after acquiring an additional 40 shares in the last quarter. U.S. Capital Wealth Advisors LLC grew its stake in shares of Becton, Dickinson and Company by 3.4% in the third quarter. U.S. Capital Wealth Advisors LLC now owns 1,310 shares of the medical instruments supplier’s stock valued at $339,000 after acquiring an additional 43 shares in the last quarter. Value Partners Investments Inc. grew its stake in shares of Becton, Dickinson and Company by 5.2% in the third quarter. Value Partners Investments Inc. now owns 867 shares of the medical instruments supplier’s stock valued at $225,000 after acquiring an additional 43 shares in the last quarter. Ridgewood Investments LLC grew its stake in shares of Becton, Dickinson and Company by 1.5% in the first quarter. Ridgewood Investments LLC now owns 2,956 shares of the medical instruments supplier’s stock valued at $731,000 after acquiring an additional 43 shares in the last quarter. Finally, Key Client Fiduciary Advisors LLC grew its stake in shares of Becton, Dickinson and Company by 2.6% in the first quarter. Key Client Fiduciary Advisors LLC now owns 1,715 shares of the medical instruments supplier’s stock valued at $424,000 after acquiring an additional 43 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on BDX. Raymond James boosted their price objective on shares of Becton, Dickinson and Company from $269.00 to $275.00 and gave the company an “outperform” rating in a report on Wednesday, January 3rd. Barclays boosted their price objective on shares of Becton, Dickinson and Company from $301.00 to $305.00 and gave the company an “overweight” rating in a report on Monday, February 5th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $280.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.